Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
Journal of Clinical Epidemiology
|
September 6, 2021
Systematic review of diabetic eye disease practice guidelines: more applicability, transparency and development rigor are needed
Rajendra Gyawali, Melinda Toomey, Fiona Stapleton, et al.
Plos One
|
March 17, 2022
Outcomes of implementation of the FilmArray meningoencephalitis panel in a tertiary hospital between 2017 and 2020
TeeKeat Teoh, James Powell, Jillian O'Keeffe, et al.
Injury Prevention : Journal of the International Society for Child and Adolescent Injury Prevention
|
February 15, 2017
PrevenTing Falls in a high-risk, vision-impaired population through specialist ORientation and Mobility services: protocol for the PlaTFORM randomised trial
Lisa Keay, Lisa Dillon, Lindy Clemson, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 19, 2003
Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis
Michael Mourez, Ming Yan, D Borden Lacy, et al.
Bioorganic & Medicinal Chemistry
|
June 15, 2007
Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase
Larry D Bratton, Bruce Auerbach, Chulho Choi, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 19, 2007
Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors
Jeffrey A Pfefferkorn, Chulho Choi, Yuntao Song, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 4, 2007
Pyrazole inhibitors of HMG-CoA reductase: an attempt to dramatically reduce synthetic complexity through minimal analog re-design
Scott D Larsen, Toni-Jo Poel, Kevin J Filipski, et al.
Journal of Medicinal Chemistry
|
December 13, 2007
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia
Jeffrey A Pfefferkorn, Chulho Choi, Scott D Larsen, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 25, 2007
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors
William K C Park, Robert M Kennedy, Scott D Larsen, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 19, 2007
Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors
Jeffrey A Pfefferkorn, Yuntao Song, Kuai-Lin Sun, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
Journal of Clinical Epidemiology
|
September 6, 2021
Systematic review of diabetic eye disease practice guidelines: more applicability, transparency and development rigor are needed
Rajendra Gyawali, Melinda Toomey, Fiona Stapleton, et al.
Plos One
|
March 17, 2022
Outcomes of implementation of the FilmArray meningoencephalitis panel in a tertiary hospital between 2017 and 2020
TeeKeat Teoh, James Powell, Jillian O'Keeffe, et al.
Injury Prevention : Journal of the International Society for Child and Adolescent Injury Prevention
|
February 15, 2017
PrevenTing Falls in a high-risk, vision-impaired population through specialist ORientation and Mobility services: protocol for the PlaTFORM randomised trial
Lisa Keay, Lisa Dillon, Lindy Clemson, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 19, 2003
Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis
Michael Mourez, Ming Yan, D Borden Lacy, et al.
Bioorganic & Medicinal Chemistry
|
June 15, 2007
Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase
Larry D Bratton, Bruce Auerbach, Chulho Choi, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 19, 2007
Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors
Jeffrey A Pfefferkorn, Chulho Choi, Yuntao Song, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 4, 2007
Pyrazole inhibitors of HMG-CoA reductase: an attempt to dramatically reduce synthetic complexity through minimal analog re-design
Scott D Larsen, Toni-Jo Poel, Kevin J Filipski, et al.
Journal of Medicinal Chemistry
|
December 13, 2007
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia
Jeffrey A Pfefferkorn, Chulho Choi, Scott D Larsen, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 25, 2007
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors
William K C Park, Robert M Kennedy, Scott D Larsen, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 19, 2007
Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors
Jeffrey A Pfefferkorn, Yuntao Song, Kuai-Lin Sun, et al.
Page
of 4